An observational study in Genetics Disease, Genetics/Birth Defects and Genetic Predisposition to Disease, sponsored by Boston Children's Hospital. Active, not recruiting at 10 sites in United States. Open to participants aged 0 Days to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Boston Children's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 297 studies in Genetic Diseases, Inborn with a site in United States — 65 open to participants now, 100 under way, 15 of them phase 3. Genetic Diseases, Inborn · United States.
Among the 297 studies in Genetic Diseases, Inborn with a site in United States, this one is the 23rd largest by enrollment of the 111 observational ones that give a count, is one of 20 that started in 2022, is one of 115 observational ones, reaches primary completion later than 23 of the 93 other live ones, and was the 223rd registered.
585 studies on the registry are indexed under Genetic Diseases, Inborn; 159 are open to participants now.
Browse Genetic Diseases, Inborn studies →65 of the 297 studies in Genetic Diseases, Inborn with a site in United States are open now. Recruiting first, the newest first:
Hemab ApS · Sites in United States
Ages 12–70
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Rocket Pharmaceuticals Inc. · Sites in United States, Netherlands
Ages 12+
Grifols Therapeutics LLC · Sites in United States, Denmark, Germany and 6 more countries
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.
This study: 0 Days to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
297 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 71 · Phase 3 49 · Phase 4 3
First in 1979; this study’s year is marked. 20 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 631 is above the median of 152 across 240 observational studies indexed under Genetic Diseases, Inborn.
Median enrollment 58 across the 166 interventional studies, 100 across the 111 observational. Of the 178 that completed or were terminated, 63 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
126 of 297 have an industry lead sponsor. The 10 most frequent:
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Boston Children's Hospital has 6 studies filed under Genetic Diseases, Inborn — fewer than ten, so there is no comparison to draw.
25 of the studies in Genetic Diseases, Inborn with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06873035Phase 3QED Therapeutics, a BridgeBio companyAn Interventional Study of Infigratinib in Children With Hypochondroplasia | 2027-01 |
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT05095727ModernaTX, Inc.A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) | 2026-11-30 |
Add all 25 to your calendar (.ics) → With an account.
Among the 297 studies in Genetic Diseases, Inborn with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will provide rigorous evaluation of implementing a virtual genome center into community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minority (URM) populations and will enhance capacity for providers and health systems to utilize highly specialized genomic techniques in their communities.
The goal of this study is to achieve equitable access to state-of-the-art genomic medical care to sick newborns in community centers that predominately care for low-income and racial/ethnic minority populations through the creation of a virtual genome center (VIGOR). VIGOR will provide a venue for physician and family education, genomic expert consultation, reanalysis of unsolved sequencing data, and access to cutting edge therapeutic innovation, thereby facilitating institutionalization of genomic best practices in community settings, and not just highly specialized referral centers.
Genomic medicine has rapidly advanced in the past decade enabling earlier diagnosis and personalized treatment. However, only a few highly specialized centers in the US have the resources to take advantage of these advances in patient care. This has created a large health equity gap whereby patients cared for in typical community settings, often low-income and/or representing racial/ethnic minorities, do not receive equitable medical care. Another barrier to the wider utilization of genomic medicine is the poor dissemination of knowledge among clinicians, especially in community settings. A wide gap exists in the implementation of genomic medicine from diagnosis to personalized therapies, a field experiencing huge advances but still subject to wide disparities in accessibility. This study aims to develop and test the implementation of a strategy to break down these barriers to genomic medicine. The target population is sick newborns admitted to the NICU that present with probable genetic conditions. This study proposes a novel center, VIrtual GenOme CenteR (VIGOR). VIGOR will be a center that can remotely support clinicians and families working in community NICUs.
This study will provide rigorous evaluation of implementing a virtual genome center at community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minorities (URM) populations and will enhance capacity for providers and health systems to utilize highly specialized genomic techniques in their communities.
The goal of this study is to achieve equitable access to state-of-the-art genomic medical care to sick newborns in community centers that predominately care for low-income and racial/ethnic minority populations through the creation of a virtual genome center (VIGOR). VIGOR will provide a venue for physician and family education, genomic expert consultation, reanalysis of unsolved sequencing data, and access to cutting edge therapeutic innovation, thereby facilitating institutionalization of genomic best practices in community settings, and not just highly specialized referral centers.
The VIGOR center will enroll and follow for 12 months 250 eligible newborns and their families within community NICUs in the US serving diverse populations. Among enrolled newborns, rapid genomic sequencing will be facilitated along with the creation and return of timely Clinical Interpretive Reports to families and providers. This study comprehensively examine implementation outcomes according to a well-established framework at the NICU, provider, and newborn/caregiver-level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Providers caring for newborns that meet eligibility criteria will approach parents to assess interest. The VIGOR study staff will remotely contact parents to complete consent for genomic sequencing (GS). We will also invite 1 additional primary caregiver (e.g. father, co-mother etc.) to participate even if that caregiver is not biologically related to the child. We will administer surveys at baseline enrollment to assess sociodemographics, obstetrical history, family genetic history \& mental health; within 1 week of disclosure of findings to assess satisfaction \& mental health; \& at 3 \& 6 months to further assess mental health \& newborn clinical outcomes. We will approach a subset of the families for qualitative interviews to assess satisfaction with VIGOR \& receipt of GS results with their physician in more detail.
Following focus groups at each of the participating sites to assess the feasibility \& needs of each site, the care teams will receive basic training in genomics and how to disclose GS results with VIGOR support. Study orientation will be completed as part of the training. Focus groups will be conducted within 1 year post implementation \& again between year 4 \& the completion of the study, to assess feasibility \& appropriateness of VIGOR. We will administer brief surveys to the care providers before \& after receipt of genomic education to assess their baseline knowledge \& comfort with genomic medicine in newborns. Surveys will be repeated within a week of disclosure to families regarding feedback on the process \& satisfaction with VIGOR. After approximately 3-5 disclosure events, study staff will approach the clinical care team members to participate in a qualitative interview to assess their perspectives in more depth.
Implementation of VIGOR
Penetration of VIGOR measured by percentage of eligible participants who were enrolled, tested, providers received CIR and completed a disclosure session.
Time frame: 4 year
Implementation of VIGOR
Appropriateness of VIGOR measured at the provider level by conducting focus groups/interviews.
Time frame: 4 year
Implementation of VIGOR
Feasibility of VIGOR measured at the provider level by conducting focus groups/interviews.
Time frame: 4 year
Service Outcomes
Equity in penetration of VIGOR use by race/ethnicity, insurance status and primary language measured at the participant level by conducting chart reviews and surveys.
Time frame: 4 years
Client Outcomes
Function measured at the infant/caregiver and provider level by conducting surveys, chart reviews and focus groups/interviews.
Time frame: 4 years
Client Outcomes
Symptomatology measured at the infant/caregiver level by conducting surveys, and interviews.
Time frame: 4 years
Client Outcomes
Satisfaction measured at the infant/caregiver and provider level by conducting surveys, chart reviews and focus groups/interviews.
Time frame: 4 years
Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.
Of 94 non-industry observational studies under Genetic Diseases, Inborn, half reached primary completion within 124 months of starting (the median), counting those still running; a quarter within 46. This study's planned 57 months is below that.
Counting every sponsor, half of 128 studies reached it within 110 months; a quarter within 46 and three quarters within 193.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.